Peptide-mediated transdermal delivery of botulinum neurotoxin type A reduces neurogenic inflammation in the skin

Pain

Volumn 149, Issue 2, 2010, Pages 316-324

  Carmichael, Nicole M E ^a   Dostrovsky, Jonathan O ^a   Charlton, Milton P ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Botulinum neurotoxin; CGRP; Neurogenic inflammation; Nociceptor; Plasma extravasation; Substance P; Transdermal drug delivery; Vasodilation

Indexed keywords

BOTULINUM TOXIN A; CALCITONIN GENE RELATED PEPTIDE; CAPSAICIN; NEUROTRANSMITTER; SUBSTANCE P; SYNTHETIC PEPTIDE;

ANALYSIS OF VARIANCE; ANIMAL EXPERIMENT; ARTICLE; BLOOD FLOW; CHRONIC INFLAMMATION; CLINICAL PRACTICE; CONTROLLED STUDY; DRUG MECHANISM; ELECTROSTIMULATION; EXOCYTOSIS; EXTRAVASATION; HINDLIMB; MALE; MEDIATOR RELEASE; MOLECULAR SIZE; NEUROGENIC INFLAMMATION; NOCICEPTIVE RECEPTOR; NONHUMAN; PAIN; POSITIVE FEEDBACK; POST HOC ANALYSIS; PRIORITY JOURNAL; RAT; SAPHENOUS NERVE; SENSORY NERVE; SKIN INFLAMMATION; VASODILATATION;

ADMINISTRATION, CUTANEOUS; ANIMALS; BOTULINUM TOXIN TYPE A; CAPSAICIN; DERMATITIS; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; ELECTRIC STIMULATION; EXOCYTOSIS; HINDLIMB; INFLAMMATION MEDIATORS; MALE; NEUROGENIC INFLAMMATION; NOCICEPTORS; PAIN; PEPTIDES; RATS; RATS, SPRAGUE-DAWLEY; SENSORY RECEPTOR CELLS; SENSORY SYSTEM AGENTS; TREATMENT OUTCOME;

EID: 77951769250     PISSN: 03043959     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pain.2010.02.024     Document Type: Article

References (55)

1. Andrews P.V., Helme R.D., and Thomas K.L. NK-1 receptor mediation of neurogenic plasma extravasation in rat skin. Br J Pharmacol 97 (1989) 1232-1238
2. Aoki K.R. Pharmacology and immunology of botulinum toxin serotypes. J Neurol 248 (2001) 3-10
3. Averbeck B., and Reeh P.W. Interactions of inflammatory mediators stimulating release of calcitonin gene-related peptide, substance P and prostaglandin E2 from isolated rat skin. Neuropharmacology 40 (2001) 416-423
4. Bach-Rojecky L., and Lackovic Z. Antinociceptive effect of botulinum toxin type A in rat model of carrageenan and capsaicin induced pain. Croat Med J 46 (2005) 201-208
5. Bach-Rojecky L., Dominis M., and Lacković Z. Lack of anti-inflammatory effect of botulinum toxin type A in experimental models of inflammation. Fundam Clin Pharmacol 22 (2008) 503-509
6. Baraniuk J.N., Kowalski M.L., and Kaliner M.A. Relationship between permeable vessels, nerves and mast cells in rat cutaneous neurogenic inflammation. J Appl Physiol 68 (1990) 2305-2311
7. Brain S.D., Williams T.J., Tippins J.R., Morris H.R., and MacIntyre L. Calcitonin gene-related peptide is a potent vasodilator. Nature 313 (1985) 54-56
8. Brain S.D., Newbold P., and Kajekar R. Modulation of the release and activity of neuropeptides in the microcirculation. Can J Physiol Pharmacol 73 (1995) 995-998
9. Carmichael N.M., Charlton M.P., and Dostrovsky J.O. Activation of the 5-HT1B/D receptor reduces hindlimb neurogenic inflammation caused by sensory nerve stimulation and capsaicin. Pain 134 (2008) 97-105
10. Carmichael N.M., Dostrovsky J.O., and Charlton M.P. Enhanced vascular permeability in rat skin induced by sensory nerve stimulation: evaluation of the time course and appropriate stimulation parameters. Neuroscience 153 (2008) 832-841
11. Chaddock J.A., Purkiss J.R., Alexander F.C., Doward S., Fooks S.J., Friis L.M., Hall Y.H., Kirby E.R., Leeds N., Moulsdale H.J., Dickenson A., Green G.M., Rahman W., Suzuki R., Duggan M.J., Quinn C.P., Shone C.C., and Foster K.A. Retargeted clostridial endopeptidases: inhibition of nociceptive neurotransmitter release in vitro, and antinociceptive activity in in vivo models of pain. Mov Disord 19 (2004) S42-S47
12. Chen Y., Shen Y., Guo X., Zhang C., Yang W., Ma M., Kiu S., Zhang M., and Wen L. Transdermal protein delivery by a coadministered peptide identified via phage display. Nat Biotechnol 24 (2006) 155-460
13. Chow A., and Wilder-Smith E.P. Effect of transdermal botulinum toxin on sweat secretion in subjects with idiopathic palmar hyperhidrosis. Br J Dermatol. 160 (2009) 721-722
14. Cui M., Khanijou S., Rubino J., and Aoki K.R. Subcutaneous administration of botulinum toxin type A reduces formalin-induced pain. Pain 107 (2004) 125-133
15. Cull-Candy S.G., Lundh H., and Thesleff S.J. Effects of botulinum toxin on neuromuscular transmission in the rat. J Physiol 260 (1976) 177-203
16. Davarian S., Kalantari K.K., Rezasoltani A., and Rahimi A. Effect and persistency of botulinum toxin iontophoresis in the treatment of palmar hyperhidrosis. Australas J Dermatol 49 (2008) 75-79
17. de Paiva A., Poulain B., Lawrence G.W., Shone C.C., Tauc L., and Dolly J.O. A role for the interchain disulfide or its participating thiols in the internalization of botulinum neurotoxin A revealed by a toxin derivative that binds to ecto-acceptors and inhibits transmitter release intracellularly. J Biol Chem 268 (1993) 20838-20844
18. Dong M., Yeh F., Tepp W.H., Dean C., Johnson E.A., Janz R., and Chapman E.R. SV2 is the receptor for botulinum neurotoxin type A. Science 312 (2006) 592
19. Dressler D., Saberi F.A., and Barbosa E.F. Botulinum toxin: mechanisms of action. Arq Neuropsiquiatr 63 (2005) 180-185
20. Durham P.L., Cady R., and Cady R. Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: implications for migraine therapy. Headache 44 (2004) 35-43
21. Gamse R., and Saria A. Potentiation of tachykinin-induced plasma protein extravasation by calcitonin gene-related peptide. Eur J Pharmacol 7 (1985) 61-66
22. Gazerani P., Staahl C., Drewes A.M., and Arendt-Nielsen L. The effects of botulinum toxin type A on capsaicin-evoked pain, flare, and secondary hyperalgesia in an experimental human model of trigeminal sensitization. Pain 122 (2006) 315-325
23. Gazerani P., Pedersen N.S., Staahl C., Drewes A.M., and Arendt-Nielsen L. Subcutaneous botulinum toxin type A reduces capsaicin-induced trigeminal pain and vasomotor reactions in human skin. Pain 141 (2009) 60-69
24. Gonzalez H.L., Carmichael N., Dostrovsky J.O., and Charlton M.P. Evaluation of the time course of plasma extravasation in the skin by digital image analysis. J Pain 6 (2005) 681-688
25. Kaufman J.L., and Karceski S. Using botulinum toxin to treat diabetic foot pain. Neurology 72 (2009) e82-e85
26. Klein A.W. The therapeutic potential of botulinum toxin. Dermatol Surg 30 (2004) 452-455
27. Kramer H.H., Angerer C., Erbguth F., Schmelz M., and Birklein F. Botulinum toxin A reduces neurogenic flare but almost no effect on pain and hyperalgesia in human skin. J Neurol 250 (2003) 188-193
28. Lebeda F.J., Adler M., Erickson K., and Chushak Y.J. Onset dynamics of type A botulinum neurotoxin-induced paralysis. Pharmacokinet Pharmacodyn 35 (2008) 251-267
29. Lee J.N., Jee S.H., Chan C.C., Lo W., Dong C.Y., and Lin S.J. The effects of depilatory agents as penetration enhancers on human stratum corneum structures. J Invest Dermatol 128 (2008) 2240-2247
30. Lembeck F., and Holzer P. Substance P as neurogenic mediator of antidromic vasodilation and neurogenic plasma extravasation. Naunyn Schmiedebergs Arch Pharmacol 310 (1979) 175-183
31. Lembeck F., Donnerer J., Tsuchiya M., and Nagahisa A. The nonpeptide tachykinin antagonist, CP 96-345, is a potent inhibitor of neurogenic inflammation. Br J Pharmacol 105 (1992) 527-530
32. Lin Q., Li D., Xu X., Zou X., and Fang L. Roles of TRPV1 and neuropeptidergic receptors in dorsal root reflex-mediated neurogenic inflammation induced by intradermal injection of capsaicin. Mol Pain 3 (2007) 30
33. Lowe N., Campanati A., Bodokh I., Cliff S., Jaen P., Kreyden O., Naumann M., Offidani A., Vadoud J., and Hamm H. The place of botulinum toxin type A in the treatment of focal hyperhidrosis. Br J Dermatol 151 (2004) 1115-1122
34. Lucioni A., Bales G.T., Lotan T.L., McGegee D.S., Cook S.P., and Dapp D.E. Botulinum toxin type A inhibits sensory neuropeptides release in rat baldder models of acute injury and chronic inflammation. BJU Int 101 (2008) 366-370
35. Lynn B., Ye W., and Cotsell B. The actions of capsaicin applied topically to the skin of the rat on C-fiber afferents, antidromic vasodilation and substance P levels. Br J Pharmacol 107 (1992) 400-406
36. Mahrhold S., Rummel A., Bigalke H., Davletov B., and Binz T. The synaptic vesicle protein 2C mediates the uptake of botulinum neurotoxin A into phrenic nerves. FEBS Lett 580 (2006) 2011-2014
37. Meng J., Wang J., Lawrence G., and Dolly J.O. Synaptobrevin I mediates exocytosis of CGRP from sensory neurons and inhibition by botulinum toxins reflects their anti-nociceptive potential. J Cell Sci 120 (2007) 2864-2874
38. Meng J., Ovsepian S.V., Wang J., Pickering M., Sasse A., Aoki K.R., Lawrence G.W., and Dolly J.O. Activation of TRPV1 mediates calcitonin gene-related peptide release, which excites trigeminal sensory neurons and is attenuated by a retargeted botulinum toxin with anti-nociceptive potential. J Neurosci 29 (2009) 4981-4992
39. Montecucco C., and Molgó J. Botulinal neurotoxins: revival of an old killer. Curr Opin Pharmacol 5 (2005) 274-279
40. Pacini S., Gulisano M., Punzi T., and Ruggiero M. Transdermal delivery of Clostridium botulinum toxin type A by pulsed current iontophoresis. J Am Acad Dermatol 57 (2007) 1097-1099
41. Prausnitz M.R., and Langer R. Transdermal drug delivery. Nat Biotechnol 26 (2008) 1261-1268
42. Purkiss J., Welch M., Doward S., and Foster K. Capsaicin-stimulated release of substance P from cultured dorsal root ganglion neurons: involvement of two distinct mechanisms. Biochem Pharmacol 59 (2000) 1403-1406
43. Ranoux D., Attal N., Morain F., and Bouhassira D. Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain. Ann Neurol 64 (2008) 274-283
44. Rapp D.E., Turk K.W., Bales G.T., and Cook S.P. Botulinum toxin type A inhibits calcitonin gene-related peptide release from isolated rat bladder. J Urol 175 (2006) 1138-1142
45. Sakaba T., Stein A., Jahn R., and Neher E. Distinct kinetic changes in neurotransmitter release after SNARE protein cleavage. Science 309 (2005) 491-494
46. Sheean G. Botulinum toxin for the treatment of musculosketetal pain and spasm. Curr Pain Headache Resp 6 (2002) 460-469
47. Suzuki R., Furuno T., McKay D.M., Wolvers D., Teshima R., Nakanishi M., and Bienenstock J. Direct neurite-mast cell communication in vitro occurs via the neuropeptide substance P. J Immunol 163 (1999) 2410-2415
48. Szolcsanyi J. Antidromic vasodilation and neurogenic inflammation. Agents Actions 23 (1988) 4-11
49. Towler P.K., and Brain S.D. Activity of tachykinin NK1and bradykinin B2 receptor antagonists, and an opioid ligand at different stimulation parameters in neurogenic inflammation in the rat. Neurosci Lett 257 (1998) 5-8
50. Tugnoli V., Capone J.G., Eleopra R., Quatrale R., Sensi M., Gastaldo E., Tola M.R., and Geppetti P. Botulinum toxin type A reduces capsaicin-evoked pain and neurogenic vasodilatation in human skin. Pain 130 (2007) 76-83
51. Verderio C., Grumelli C., Raiteri L., Coco S., Paluzzi S., Caccin P., Rossetto O., Bonanno G., Montecucco C., and Matteoli M. Traffic of botulinum toxins A and E in excitatory and inhibitory neurons. Traffic 8 (2007) 142-153
52. Voller B., Sycha T., Gustorff B., Schmetterer L., Lehr S., Eichler H.G., Auff E., and Schnider P. A randomized, double-blind, placebo controlled study on analgesic effects of botulinum toxin A. Neurology 61 (2003) 940-944
53. Welch M.J., Purkiss J.R., and Foster K.A. Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins. Toxicon 38 (2000) 245-258
54. Yoon H., Chung W.S., and Shim B.S. Botulinum toxin A for the management of vulvodynia. Int J Impot Res 19 (2007) 84-87
55. Yuan R.Y., Sheu J.J., Yu J.M., Chen W.T., Tseng I.J., Chang H.H., and Hu C.J. Botulinum toxin for diabetic neuropathic pain: a randomized double-blind crossover trial. Neurology 72 (2009) 1473-1478